Drugplain

Technetium Tc 99m Medronate 25 mg/1

Technetium Tc 99m Medronate · INJECTION, POWDER, FOR SOLUTION · Jubilant DraxImage Inc., dba Jubilant Radiopharma

No Recall HistoryCurrently in Shortage
Plain English

Technetium Tc 99m Medronate is a injection, powder, for solution containing technetium tc 99m medronate at 25 mg/1, taken intravenous. Manufactured by Jubilant DraxImage Inc., dba Jubilant Radiopharma.

Key Facts

Brand Name
Technetium Tc 99m Medronate
Generic Name
Technetium Tc 99m Medronate
NDC Code (Product)
65174-660
Manufacturer
Jubilant DraxImage Inc., dba Jubilant Radiopharma
Strength
25 mg/1
Dosage Form
INJECTION, POWDER, FOR SOLUTION
Route
INTRAVENOUS
Marketing Status
Application #
NDA018035
Marketing Start
02/27/2004

Recall History

No Recall History

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

pruritus2 reports
chills1 reports
dysphagia1 reports
erythema1 reports
eye oedema1 reports
eye pain1 reports
hypersensitivity1 reports
hypoaesthesia1 reports
mucosal inflammation1 reports
palpitations1 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

INDICATIONS AND USAGE MDP-25 (Kit for the Preparation of Technetium Tc 99m Medronate) may be used as a bone imaging agent to delineate areas of altered osteogenesis.

Dosage & Administration

DOSAGE AND ADMINISTRATION The recommended adult dose, after reconstitution with oxidant-free sodium pertechnetate Tc-99m, is 370 to 740 megabecquerels (10 to 20 millicuries [200 µCi/kg]) by slow intravenous injection over a period of 30 seconds. Optimum scanning time is 1 to 4 hours post-injection. To minimize the contribution of the bladder content to the image, the patient should void immediately before imaging is started. The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. The solution should not be used if cloudy. RADIATION DOSIMETRY The estimated absorbed radiation doses to an average patient (70 kg) from an intravenous injection of a maximum dose of 740 megabecquerels (20 millicuries) of Technetium Tc 99m Medronate are shown in Table 4. The effective half-life was assumed to be the physical half-life for all calculated values. Table 4 Radiation Doses 2 Tissue Absorbed Radiation Dose mGy/740 MBq rads/20 mCi Total Body Total Bone Red Marrow Kidneys Liver Bladder Wall 2 hr. void 4.8 hr. void Ov

Warnings

WARNINGS This class of compounds is known to complex cations such as calcium. Particular caution should be used with patients who have, or who may be predisposed to, hypocalcemia (i.e., alkalosis). The contents of the kit before preparation are not radioactive. However, after the sodium pertechnetate Tc-99m is added, adequate shielding of the final preparation must be maintained. Preliminary reports indicate impairment of brain images using Sodium Pertechnetate Tc 99m Injection which have been preceded by bone imaging using an agent containing stannous ions. The impairment may result in false-positive or false-negative brain images. It is recommended, where feasible, that brain imaging using Sodium Pertechnetate Tc 99m Injection precede bone imaging procedures. Alternatively, a brain imaging agent such as technetium Tc-99m pentetate may be employed. The biodistribution of technetium Tc 99m medronate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). This may result in reduced uptake of radionuclide in the skeleton and increased extraosseal uptake, which may potentially degrade imaging quality. High levels of these cations may be caused b

Contraindications

CONTRAINDICATIONS None known.

Adverse Reactions

ADVERSE REACTIONS Several cases of allergic dermatological reactions have been reported in association with the use of Technetium Tc 99m Medronate. Several reactions have also been reported in association with other radiopharmaceuticals of the diphosphonate class, particularly Technetium Tc 99m Medronate. These are usually hypersensitivity reactions characterized by itching, various skin rashes, hypotension, chills, nausea, fever, and vomiting. One death secondary to cardiac arrhythmia following the administration of Technetium Tc 99m Medronate has been reported. In addition, one case of cardiac arrest in a patient also undergoing pulmonary function testing one and one-half hours after the performance of a bone scan using Technetium Tc 99m Medronate has been reported.

Frequently Asked Questions

What is Technetium Tc 99m Medronate used for?

Technetium Tc 99m Medronate contains Technetium Tc 99m Medronate. It is a injection, powder, for solution taken intravenous. Consult your doctor for specific uses.

Is Technetium Tc 99m Medronate a controlled substance?

Technetium Tc 99m Medronate is not classified as a controlled substance by the DEA.

What is the generic name for Technetium Tc 99m Medronate?

The generic name for Technetium Tc 99m Medronate is Technetium Tc 99m Medronate. There are 1 other brand versions of Technetium Tc 99m Medronate.

What is the NDC code for Technetium Tc 99m Medronate 25 mg/1?

The NDC (National Drug Code) for Technetium Tc 99m Medronate 25 mg/1 is 65174-660, listed by Jubilant DraxImage Inc., dba Jubilant Radiopharma.

Product NDC

65174-660

Package NDC

65174-660-30

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)